DW91170 / Dong Wha - LARVOL DELTA

DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment (AACR 2023) - "In order to verify the potential of DW91170 in R/R-lymphoma patients, the anti-cancer effect was evaluated in Rituximab-resistant cell line and R/R-DLBCL patient-derived PDX model. Taken together, we demonstrated that DW91170, a dual epigenetic regulator of EZH1 and EZH2, showed great anti-tumor activities in various lymphoma cell lines and animal models such as CDX and PDX. We are currently trying to expand indication into solid tumor to find a targetable population in clinical trials."

Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • EZH2